{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:29:23Z","timestamp":1794558563826,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-025-05684-1","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:45:18Z","timestamp":1764233118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Predictive enrichment using biomarkers in studies of critically-ill patients with sepsis: a systematic review"],"prefix":"10.1186","volume":"29","author":[{"given":"Logan R.","family":"Van Nynatten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diyaa","family":"Bokhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Yee Suet","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Fero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McChesney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Fiorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leann","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas D.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Slessarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Leligdowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Rochwerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Basmaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"5684_CR1","doi-asserted-by":"crossref","unstructured":"Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, \u00d1amendys-Silva SA, Martin-Loeches I, Leone M, Lupu M-N, Vincent J-L. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open forum infectious diseases: 2018. Oxford University Press US; 2018. p. ofy313.","DOI":"10.1093\/ofid\/ofy313"},{"issue":"4","key":"5684_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/CCM.0b013e3181d455b6","volume":"38","author":"\u00c1 Castellanos-Ortega","year":"2010","unstructured":"Castellanos-Ortega \u00c1, Suberviola B, Garc\u00eda-Astudillo LA, Holanda MS, Ortiz F, Llorca J, et al. Impact of the surviving sepsis campaign protocols on hospital length of stay and mortality in septic shock patients: results of a three-year follow-up quasi-experimental study. Crit Care Med. 2010;38(4):1036\u201343.","journal-title":"Crit Care Med"},{"issue":"4","key":"5684_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","volume":"20","author":"JC Marshall","year":"2014","unstructured":"Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195\u2013203.","journal-title":"Trends Mol Med"},{"issue":"1","key":"5684_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/CCM.0b013e31819285f0","volume":"37","author":"CM Martin","year":"2009","unstructured":"Martin CM, Priestap F, Fisher H, Fowler RA, Heyland DK, Keenan SP, et al. A prospective, observational registry of patients with severe sepsis: the Canadian sepsis treatment and response registry. Crit Care Med. 2009;37(1):81\u20138.","journal-title":"Crit Care Med"},{"issue":"3","key":"5684_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1164\/rccm.201504-0781OC","volume":"193","author":"C Fleischmann","year":"2016","unstructured":"Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3):259\u201372.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"5684_CR6","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s00134-020-06151-x","volume":"46","author":"C Fleischmann-Struzek","year":"2020","unstructured":"Fleischmann-Struzek C, Mellhammar L, Rose N, Cassini A, Rudd KE, Schlattmann P, et al. Incidence and mortality of hospital-and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020;46(8):1552.","journal-title":"Intensive Care Med"},{"issue":"7","key":"5684_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1164\/rccm.200903-0363OC","volume":"180","author":"C Meisel","year":"2009","unstructured":"Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, et al. Granulocyte\u2013macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"5684_CR8","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/jama.2017.13836","volume":"318","author":"C Rhee","year":"2017","unstructured":"Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009\u20132014. JAMA. 2017;318(13):1241\u20139.","journal-title":"JAMA"},{"issue":"9","key":"5684_CR9","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00134-018-5175-z","volume":"44","author":"CM Coopersmith","year":"2018","unstructured":"Coopersmith CM, De Backer D, Deutschman CS, Ferrer R, Lat I, Machado FR, et al. Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive Care Med. 2018;44(9):1400\u201326.","journal-title":"Intensive Care Med"},{"key":"5684_CR10","doi-asserted-by":"crossref","unstructured":"Yarnell CJ, Fralick M. Heterogeneity of treatment effect\u2014an evolution in subgroup analysis. In., vol. 3: Massachusetts Medical Society; 2024: EVIDe2400054.","DOI":"10.1056\/EVIDe2400054"},{"key":"5684_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fsci.2025.1557323","volume":"3","author":"RP Dellinger","year":"2025","unstructured":"Dellinger RP, Bartock J. Transforming sepsis heterogeneity: challenges and progress. Front Sci. 2025;3:1557323.","journal-title":"Front Sci"},{"issue":"1","key":"5684_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13054-019-2446-1","volume":"23","author":"S Santhakumaran","year":"2019","unstructured":"Santhakumaran S, Gordon A, Prevost AT, O\u2019Kane C, McAuley DF, Shankar-Hari M. Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. Crit Care. 2019;23(1):156.","journal-title":"Crit Care"},{"issue":"9","key":"5684_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1164\/rccm.201411-2125CP","volume":"192","author":"TJ Iwashyna","year":"2015","unstructured":"Iwashyna TJ, Burke JF, Sussman JB, Prescott HC, Hayward RA, Angus DC. Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care. Am J Respir Crit Care Med. 2015;192(9):1045\u201351.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"5684_CR14","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.chest.2021.07.009","volume":"160","author":"YA Khan","year":"2021","unstructured":"Khan YA, Fan E, Ferguson ND. Precision medicine and heterogeneity of treatment effect in therapies for ARDS. Chest. 2021;160(5):1729\u201338.","journal-title":"Chest"},{"issue":"19","key":"5684_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"5684_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"5684_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med"},{"issue":"11","key":"5684_CR18","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063\u2013143.","journal-title":"Crit Care Med"},{"issue":"8","key":"5684_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"key":"5684_CR20","doi-asserted-by":"crossref","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovi\u0107 J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. bmj 2011, 343.","DOI":"10.1136\/bmj.d5928"},{"key":"5684_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100817","author":"K Leventogiannis","year":"2022","unstructured":"Leventogiannis K, Kyriazopoulou E, Antonakos N, Kotsaki A, Tsangaris I, Markopoulou D et al. Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial. Cell Rep Med. 2022;3(11):100817. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100817","journal-title":"Cell Rep Med"},{"issue":"11","key":"5684_CR22","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1097\/01.CCM.0000145229.59014.6C","volume":"32","author":"EA Panacek","year":"2004","unstructured":"Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F (ab\u2032) 2 fragment Afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med. 2004;32(11):2173\u201382.","journal-title":"Crit Care Med"},{"issue":"4","key":"5684_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1097\/00003246-200104000-00015","volume":"29","author":"K Reinhart","year":"2001","unstructured":"Reinhart K, Menges T, Gardlund B, Zwaveling JH, Smithes M, Vincent J-L, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment Afelimomab in hyperinflammatory response during severe sepsis: the RAMSES study. Crit Care Med. 2001;29(4):765\u20139.","journal-title":"Crit Care Med"},{"issue":"39","key":"5684_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017354","volume":"98","author":"J Guan","year":"2019","unstructured":"Guan J, Guo Y, Chang P, Gan J, Zhou J, Wang H, et al. Adjunctive granisetron therapy in patients with sepsis or septic shock (GRANTISS): study protocol for a randomized controlled trial. Medicine (Baltimore). 2019;98(39):e17354.","journal-title":"Medicine (Baltimore)"},{"key":"5684_CR25","doi-asserted-by":"crossref","unstructured":"Guan J, Liao Y, Guo Y, Yu S, Wei R, Niu M, Gan J, Zhang L, Li T, Lv J: Adjunctive granisetron therapy in patients with sepsis or septic shock (GRANTISS): A single-center, single-blinded, randomized, controlled clinical trial. Frontiers in Pharmacology. 2022;13:1013284.","DOI":"10.3389\/fphar.2022.1013284"},{"issue":"1","key":"5684_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-024-04825-2","volume":"28","author":"ME Adami","year":"2024","unstructured":"Adami ME, Kotsaki A, Antonakos N, Giannitsioti E, Chalvatzis S, Saridaki M, et al. QSOFA combined with SuPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial. Crit Care. 2024;28(1):42.","journal-title":"Crit Care"},{"issue":"11","key":"5684_CR27","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00134-021-06537-5","volume":"47","author":"P-F Laterre","year":"2021","unstructured":"Laterre P-F, Pickkers P, Marx G, Wittebole X, Meziani F, Dugernier T, et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial. Intensive Care Med. 2021;47(11):1284\u201394.","journal-title":"Intensive Care Med"},{"issue":"9","key":"5684_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.32444","volume":"7","author":"MH Bestle","year":"2024","unstructured":"Bestle MH, Stensballe J, Lange T, Clausen NE, S\u00f8e-Jensen P, Pedersen KH, et al. Iloprost and organ dysfunction in adults with septic shock and endotheliopathy: a randomized clinical trial. JAMA Netw Open. 2024;7(9):e2432444\u20132432444.","journal-title":"JAMA Netw Open"},{"key":"5684_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc13163","volume":"17","author":"S Gando","year":"2013","unstructured":"Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013;17:1\u201310.","journal-title":"Crit Care"},{"issue":"14","key":"5684_CR30","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455\u201363.","journal-title":"JAMA"},{"issue":"1","key":"5684_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2077-y","volume":"22","author":"N Srisawat","year":"2018","unstructured":"Srisawat N, Tungsanga S, Lumlertgul N, Komaenthammasophon C, Peerapornratana S, Thamrongsat N, et al. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Crit Care. 2018;22(1):279.","journal-title":"Crit Care"},{"key":"5684_CR32","unstructured":"Tungsanga S, Lumlertgul N, Thamrongsat N, Peerapornratana S, Tungsanga K, Srisawat N. Polymyxin B Hemoperfusion Shows No Benefits on Kidney Outcomes in Severe Sepsis Patients. ASN Kidney Week, October 26, 2018, San Diego Convention Center. Abstract FR-OR020."},{"issue":"1","key":"5684_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-022-00602-x","volume":"10","author":"V D\u2019Onofrio","year":"2022","unstructured":"D\u2019Onofrio V, Heylen D, Pusparum M, Grondman I, Vanwalleghem J, Meersman A, et al. A prospective observational cohort study to identify inflammatory biomarkers for the diagnosis and prognosis of patients with sepsis. J Intensive Care. 2022;10(1):13.","journal-title":"J Intensive Care"},{"issue":"1","key":"5684_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03862-5","volume":"26","author":"T Barichello","year":"2022","unstructured":"Barichello T, Generoso JS, Singer M, Dal-Pizzol F. Biomarkers for sepsis: more than just fever and leukocytosis\u2014a narrative review. Crit Care. 2022;26(1):14.","journal-title":"Crit Care"},{"key":"5684_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00691","volume":"9","author":"KA Mosevoll","year":"2018","unstructured":"Mosevoll KA, Skrede S, Markussen DL, Fanebust HR, Flaatten HK, A\u00dfmus J, et al. Inflammatory mediator profiles differ in sepsis patients with and without bacteremia. Front Immunol. 2018;9:691.","journal-title":"Front Immunol"},{"issue":"1","key":"5684_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41581-019-0199-3","volume":"16","author":"NL Stanski","year":"2020","unstructured":"Stanski NL, Wong HR. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol. 2020;16(1):20\u201331.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"5684_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41390-021-01620-5","volume":"91","author":"HR Wong","year":"2022","unstructured":"Wong HR. Pediatric sepsis biomarkers for prognostic and predictive enrichment. Pediatr Res. 2022;91(2):283\u20138.","journal-title":"Pediatr Res"},{"issue":"9","key":"5684_CR38","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S2213-2600(18)30279-0","volume":"6","author":"JG Laffey","year":"2018","unstructured":"Laffey JG, Kavanagh BP. Negative trials in critical care: why most research is probably wrong. Lancet Respir Med. 2018;6(9):659\u201360.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"5684_CR39","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","volume":"25","author":"SM Opal","year":"1997","unstructured":"Opal SM, Fisher CJ, Dhainaut J-FA, Vincent J-L, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, doubleblind, placebo-controlled, multicenter trial. Crit Care Med. 1997;25(7):1115\u201324.","journal-title":"Crit Care Med"},{"issue":"9107","key":"5684_CR40","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(05)60602-2","volume":"351","author":"E Abraham","year":"1998","unstructured":"Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet. 1998;351(9107):929\u201333.","journal-title":"Lancet"},{"issue":"11","key":"5684_CR41","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00134-023-07239-w","volume":"49","author":"RB van Amstel","year":"2023","unstructured":"van Amstel RB, Kennedy JN, Scicluna BP, Bos LD, Peters-Sengers H, Butler JM, Cano-Gamez E, Knight JC, Vlaar AP, Cremer OL. Uncovering heterogeneity in sepsis: a comparative analysis of subphenotypes. Intensive Care Med. 2023;49(11):1360\u20139.","journal-title":"Intensive Care Med"},{"key":"5684_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-13-126","volume":"13","author":"K-Q Liu","year":"2012","unstructured":"Liu K-Q, Liu Z-P, Hao J-K, Chen L, Zhao X-M. Identifying dysregulated pathways in cancers from pathway interaction networks. BMC Bioinformatics. 2012;13:1\u201311.","journal-title":"BMC Bioinformatics"},{"key":"5684_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11684-014-0318-2","volume":"8","author":"X Liu","year":"2014","unstructured":"Liu X, Ren H, Peng D. Sepsis biomarkers: an omics perspective. Front Med. 2014;8:58\u201367.","journal-title":"Front Med"},{"issue":"1","key":"5684_CR44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10020-022-00548-8","volume":"28","author":"MA Patel","year":"2022","unstructured":"Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Martin C, et al. Elevated vascular transformation blood biomarkers in long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol Med. 2022;28(1):122.","journal-title":"Mol Med"},{"issue":"5","key":"5684_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/prca.202300233","volume":"18","author":"H Wang","year":"2024","unstructured":"Wang H, Zhao T, Zeng J, Zhang R, Pu L, Qian S, et al. Methods and clinical biomarker discovery for targeted proteomics using Olink technology. PROTEOMICS \u2013 Clinical Applications. 2024;18(5):2300233.","journal-title":"PROTEOMICS \u2013 Clinical Applications"},{"issue":"5","key":"5684_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.nbt.2011.11.016","volume":"29","author":"L Gold","year":"2012","unstructured":"Gold L, Walker JJ, Wilcox SK, Williams S. Advances in human proteomics at high scale with the SOMAscan proteomics platform. New Biotechnol. 2012;29(5):543\u20139.","journal-title":"New Biotechnol"},{"issue":"1","key":"5684_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04149-9","volume":"21","author":"C Iosef","year":"2023","unstructured":"Iosef C, Knauer MJ, Nicholson M, Van Nynatten LR, Cepinskas G, Draghici S, et al. Plasma proteome of long-COVID patients indicates HIF-mediated vasculo-proliferative disease with impact on brain and heart function. J Transl Med. 2023;21(1):377.","journal-title":"J Transl Med"},{"issue":"1","key":"5684_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-022-09389-3","volume":"19","author":"LR Van Nynatten","year":"2022","unstructured":"Van Nynatten LR, Slessarev M, Martin CM, Leligdowicz A, Miller MR, Patel MA, et al. Novel plasma protein biomarkers from critically ill sepsis patients. Clin Proteomics. 2022;19(1):50.","journal-title":"Clin Proteomics"},{"key":"5684_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104394","author":"M Komorowski","year":"2022","unstructured":"Komorowski M, Green A, Tatham KC, Seymour C, Antcliffe D. Sepsis biomarkers and diagnostic tools with a focus on machine learning. EBioMedicine. 2022. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104394","journal-title":"EBioMedicine"},{"issue":"D1","key":"5684_CR50","doi-asserted-by":"publisher","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","volume":"46","author":"A Fabregat","year":"2018","unstructured":"Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B. The reactome pathway knowledgebase. Nucleic Acids Res. 2018;46(D1):D649\u201355.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"5684_CR51","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45(D1):D353-61.","journal-title":"Nucleic Acids Res"},{"key":"5684_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-018-2533-3","volume":"19","author":"M Pomaznoy","year":"2018","unstructured":"Pomaznoy M, Ha B, Peters B. Gonet: a tool for interactive gene ontology analysis. BMC Bioinformatics. 2018;19:1\u20138.","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"5684_CR53","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","volume":"14","author":"J Reimand","year":"2019","unstructured":"Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, et al. Pathway enrichment analysis and visualization of omics data using g: profiler, GSEA, cytoscape and enrichmentmap. Nat Protoc. 2019;14(2):482\u2013517.","journal-title":"Nat Protoc"},{"issue":"1","key":"5684_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49986-4","volume":"15","author":"M Slobodyanyuk","year":"2024","unstructured":"Slobodyanyuk M, Bahcheli AT, Klein ZP, Bayati M, Strug LJ, Reimand J. Directional integration and pathway enrichment analysis for multi-omics data. Nat Commun. 2024;15(1):5690.","journal-title":"Nat Commun"},{"issue":"4","key":"5684_CR55","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.tig.2023.01.003","volume":"39","author":"K Zhao","year":"2023","unstructured":"Zhao K, Rhee SY. Interpreting omics data with pathway enrichment analysis. Trends Genet. 2023;39(4):308\u201319.","journal-title":"Trends Genet"},{"key":"5684_CR56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jpba.2014.12.017","volume":"113","author":"R Bujak","year":"2015","unstructured":"Bujak R, Struck-Lewicka W, Markuszewski MJ, Kaliszan R. Metabolomics for laboratory diagnostics. J Pharm Biomed Anal. 2015;113:108\u201320.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"5684_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-023-02317-4","volume":"23","author":"H She","year":"2023","unstructured":"She H, Du Y, Du Y, Tan L, Yang S, Luo X, et al. Metabolomics and machine learning approaches for diagnostic and prognostic biomarkers screening in sepsis. BMC Anesthesiol. 2023;23(1):367.","journal-title":"BMC Anesthesiol"},{"issue":"10","key":"5684_CR58","volume":"2","author":"DD Fraser","year":"2020","unstructured":"Fraser DD, Slessarev M, Martin CM, Daley M, Patel MA, Miller MR, et al. Metabolomics profiling of critically ill coronavirus disease 2019 patients: identification of diagnostic and prognostic biomarkers. Crit Care Explor. 2020;2(10):e0272.","journal-title":"Crit Care Explor"},{"key":"5684_CR59","doi-asserted-by":"publisher","unstructured":"Palmowski L, Weber M, Bayer M, Mi Y, Schork K, Eisenacher M, Nowak H et al. Mortality-associated plasma proteome dynamics in a prospective multicentre sepsis cohort. EBioMedicine. 2025;111:105508. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105508.","DOI":"10.1016\/j.ebiom.2024.105508"},{"issue":"8","key":"5684_CR60","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"CS Calfee","year":"2014","unstructured":"Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611\u201320.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"5684_CR61","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1164\/rccm.201603-0645OC","volume":"195","author":"KR Famous","year":"2017","unstructured":"Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195(3):331\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"5684_CR62","unstructured":"Reddy K, Aggarwal N, Alipanah-Lechner N, Annane D, Antcliffe DB, Babalis D et al. Building an international precision medicine platform trial for the acute respiratory distress syndrome (ARDS): an expert consensus project report [Internet]. Southampton (UK): National Institute for Health and Care Research. 2025;1\u201343."},{"issue":"10","key":"5684_CR63","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","volume":"27","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with Anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752\u201360.","journal-title":"Nat Med"},{"key":"5684_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101785","author":"K Akinosoglou","year":"2023","unstructured":"Akinosoglou K, Kotsaki A, Gounaridi I-M, Christaki E, Metallidis S, Adamis G, et al. Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial. eClinicalMedicine. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101785.","journal-title":"eClinicalMedicine"},{"issue":"10285","key":"5684_CR65","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"Group RC","year":"2021","unstructured":"Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637.","journal-title":"Lancet"},{"issue":"12","key":"5684_CR66","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","volume":"181","author":"AC Spyropoulos","year":"2021","unstructured":"Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612\u201320.","journal-title":"JAMA Intern Med"},{"issue":"9713","key":"5684_CR67","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","volume":"375","author":"L Bouadma","year":"2010","unstructured":"Bouadma L, Luyt C-E, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients\u2019 exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463\u201374.","journal-title":"Lancet"},{"issue":"10","key":"5684_CR68","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/rccm.201408-1483OC","volume":"190","author":"Y Shehabi","year":"2014","unstructured":"Shehabi Y, Sterba M, Garrett PM, Rachakonda KS, Stephens D, Harrigan P, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med. 2014;190(10):1102\u201310.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"5684_CR69","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","volume":"16","author":"E de Jong","year":"2016","unstructured":"de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819\u201327.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"5684_CR70","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","volume":"199","author":"DB Antcliffe","year":"2019","unstructured":"Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, et al. Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial. Am J Respir Crit Care Med. 2019;199(8):980\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"5684_CR71","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00134-018-5463-7","volume":"44","author":"D Klein","year":"2018","unstructured":"Klein D, Foster D, Walker P, Bagshaw S, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44(12):2205\u201312.","journal-title":"Intensive Care Med"},{"key":"5684_CR72","doi-asserted-by":"crossref","unstructured":"Kiernan E, Zelnick LR, Khader A, Coston TD, Bailey ZA, Speckmaier S, Lo JJ, Siew ED, Sathe NA, Kestenbaum BR. Molecular phenotyping of sepsis and differential response to fluid resuscitation. American Journal of Respiratory and Critical Care Medicine 2025(ja).","DOI":"10.21203\/rs.3.rs-4523416\/v1"},{"issue":"9","key":"5684_CR73","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","volume":"202","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, et al. Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med. 2020;202(9):1253\u201361.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-025-05684-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05684-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:02:07Z","timestamp":1764237727000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-025-05684-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5684"],"URL":"https:\/\/doi.org\/10.1186\/s13054-025-05684-1","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"504"}}